Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

Pascal Sève1, Charles Dumontet

  • 1Université Claude Bernard Lyon, Lyon, France. pascal.seve@chu-lyon.fr

The Lancet. Oncology
|February 2, 2008

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Is Class Iii Beta-tubulin A Predictive Factor In Patients Receiving Tubulin-binding Agents?

    • High class III beta-tubulin expression predicts poor outcomes with certain chemotherapy agents, but may be overcome by others, suggesting it

    Area of Science:

    • Oncology
    • Molecular Biology
    • Clinical Research

    Background:

    • Preclinical studies indicate class III beta-tubulin overexpression correlates with resistance to tubulin-binding chemotherapy agents.
    • Clinical observations suggest a link between high class III beta-tubulin expression and poorer treatment outcomes in various cancers.

    Purpose of the Study:

    • To investigate the prognostic and predictive value of class III beta-tubulin in patients undergoing chemotherapy.
    • To determine if class III beta-tubulin expression influences treatment response and survival across different cancer types and therapeutic regimens.

    Main Methods:

    • Review of preclinical data and clinical studies examining class III beta-tubulin expression in relation to patient outcomes.
    • Analysis of patient samples from trials involving tubulin-binding agents (e.g., taxanes, vinorelbine) and non-tubulin-binding agents.
    • Correlation of class III beta-tubulin levels with response rates, survival, and baseline patient/tumor characteristics.

    Main Results:

    • High class III beta-tubulin expression is associated with reduced response and survival in non-small-cell lung cancer (NSCLC) patients treated with paclitaxel.
    • This predictive association was not observed in patients receiving non-tubulin-binding agents.
    • In the JBR-10 trial, chemotherapy (cisplatin/vinorelbine) appeared to overcome the negative prognostic effect of high class III beta-tubulin in NSCLC.
    • High class III beta-tubulin expression correlated with younger age, specific NSCLC histologies (adenocarcinoma, large-cell), and advanced disease stage.

    Conclusions:

    • Class III beta-tubulin may serve as both a prognostic and predictive biomarker in cancer treatment.
    • Its clinical utility might depend on the specific chemotherapy regimen and cancer type.
    • Further large-scale randomized trials are necessary to definitively establish the prognostic and predictive roles of class III beta-tubulin in diverse clinical settings.

    Related Experiment Videos